3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Multiple Myeloma
2
Epstein-Barr Virus Infections
2
Cytomegalovirus Infections
2
Colorectal Neoplasms
2
Adenoviridae Infections
2
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunologic Deficiency Syndromes
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Glioblastoma
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Temozolomide
264
Radiotherapy
119
Bevacizumab
105
Magnetic Resonance Spectroscopy
59
Radiation
47
pembrolizumab
30
Irinotecan
28
Surgical Procedures, Operative
23
Lomustine
21
Specimen Handling
19
Nivolumab
19
Radiosurgery
18
Carmustine
18
Aminolevulinic Acid
16
Erlotinib Hydrochloride
15
Drug Therapy
15
Blood Specimen Collection
14
Radiotherapy, Intensity-Modulated
13
O(6)-benzylguanine
13
Chemotherapy, Adjuvant
13
Carboplatin
13
Filgrastim
11
Cyclophosphamide
11
sargramostim
10
poly ICLC
10
atezolizumab
10
Thalidomide
10
Etoposide
10
Ipilimumab
9
Everolimus
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Glioblastoma
×
Cell Count
×
Clear all
NCT07144735
2025-08-27
ABOUT
Peking University Third Hospital
Phase NA
Recruiting
18 enrolled